ARCHIVES

FDA Commissioner Says Swifter Drug Approvals, Enforcement Emphasis Characterize ‘Today’s FDA’

This article is from The Cancer Letter archive.

Vol. 18 No. 05 | January 31, 1992

Download PDF Visit The Full Archive

Related Articles

President Proposes 2.1% Incerase for NIH, 2.4% Increase for NCI, In Year 2000 Budget

February 5, 1999

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013

Mozobil Plus G-CSF Increases Rate Of Cell Mobilization

September 30, 2005

Don’t Blame FDA For All Problems, Broder Says

September 7, 1990

Release of Mayo Pathology Report Would Be Needed To Confirm Stage IIA Diagnosis.

October 24, 2008

New NCAB Appointees Include Some Old Hands; Korn Renamed Chairman

May 13, 1988